AccuVein announces $22.

Current investors participated also. Regarding the the financing, Eric Bednarski of MVM Life Technology Partners and Christopher Gabrieli of Bessemer Venture Companions have joined the AccuVein board. Aquilo Partners, L.P., a life science investment bank, acted as the exclusive placement agent for the funding. We are impressed by AccuVein’s proprietary technology and commercial execution and are excited to work with the company to improve patient care by making vein illumination broadly available to sufferers and clinicians, stated Dr.We were holding treated as irritable bowel syndrome. Treatment, which included anti-spasmodics and pain medicine, proved ineffective. She underwent numerous tests: blood work, gynecological work-ups, a scope of her bladder, both top and lower GI colonoscopy and endoscopy. After performing the latter, her gastroenterologist recommended exploratory surgery, however the doctor thought it unnecessary. A barium enema accompanied by an X-ray also uncovered nothing. Her primary doctor referred her to another gastroenterologist, who ordered a CAT scan.

You may also like